Explore / Peer-reviewed article
Peer-reviewed articleOpen access

New psychoactive substances: a review and updates.

Shafi A, Berry AJiD, Sumnall HiD, Wood DMiD, Tracy DKiD

Therapeutic advances in psychopharmacologyDec 17, 2020License: open accessUnited Kingdom201 citationsDOI: 10.1177/2045125320967197

Abstract

New psychoactive substances (NPS) are a heterogeneous group of substances. They are associated with a number of health and social harms on an individual and societal level. NPS toxicity and dependence syndromes are recognised in primary care, emergency departments, psychiatric inpatient and community care settings. One pragmatic classification system is to divide NPS into one of four groups: synthetic stimulants, synthetic cannabinoids, synthetic hallucinogens and synthetic depressants (which include synthetic opioids and benzodiazepines). We review these four classes of NPS, including their chemical structures, mechanism of action, modes of use, intended intoxicant effects, and their associated physical and mental health harms. The current challenges faced by laboratory testing for NPS are also explored, in the context of the diverse range of NPS currently available, rate of production and emergence of new substances, the different formulations, and methods of acquisition and distribution.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsychedelicsAddiction

Keywords

Laboratory TestingNpsNew Psychoactive SubstancesSynthetic OpioidsSynthetic StimulantsSynthetic Cannabinoid Receptor AgonistsSynthetic Hallucinogens

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.